Peptron stock falls 30% following news of 신규 바카라사이트’s similar technology… “Co-development remains on track”
[by Ji, Yong Jun] Peptron announced on June 4 that the technology evaluation contract for the development of the long-acting obesity treatment, 'SmartDepot,' in collaboration with Eli Lilly in the United States, is progressing smoothly.
Peptron recently provided this clarification following Eli 신규 바카라사이트’s licensing-in (L/I) agreement for the long-acting technology of Sweden's Camurus, which raised concerns about the non-exclusive contract between Peptron and Eli 신규 바카라사이트 signed in October 2024. In point of fact, Peptron's stock price (based on the closing price) fell by 30% from the previous trading day, closing at KRW 161,000 (approximately USD 118).
On June 3 (local time), Eli 신규 바카라사이트 announced the signing of an agreement to acquire Camurus' drug delivery platform, 'FluidCrystal,' for the development of long-acting incretin-based treatments, with a total contract value of up to USD 870 million (approximately KRW 1.1962 trillion). The contract includes dual inhibitory peptides (GIP) and glucagon-like peptide 1 (GLP-1) agents, triple inhibitory peptides (GIP), GLP-1, and glucagon, and amylin receptor agonists, with the possibility of including additional compounds from Eli 신규 바카라사이트 as needed. Given that the agreement for 'FluidCrystal' has been specifically disclosed, there are market concerns that the status of SmartDepot, currently under a non-exclusive agreement with Eli 신규 바카라사이트 and considered a competing technology, may be adversely affected.
Peptron emphasized that "the technology evaluation for the development of a long-term obesity treatment with 신규 바카라사이트 is still ongoing." The company further clarified that "Camurus’ technology is entirely different from Peptron's SmartDepot and should not be regarded as a direct competitor" and confirmed that "discussions with Eli 신규 바카라사이트 will proceed as planned."